Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07335341 · ClinicalTrials.gov registry record
Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System
A clinical trial, sponsored by Medtronic Endovascular.
- Recruiting
- Registry status
- 50
- Enrollment target
NCT07335341: Recruiting study, sponsored by Medtronic Endovascular.
NCT07335341 is a clinical trial that is actively recruiting participants, run by Medtronic Endovascular. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07335341 is actively recruiting participants, sponsored by Medtronic Endovascular.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
Study Summary
The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems
Primary Outcome
An Adverse Event that converted to Serious Adverse Event, involving the function of the subject device, or the presence of the device in the body, including events that are directly attributable to the Liberant Thrombectomy System
Interventions
- DEVICE Liberant Thrombectomy System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2026-10 |
What NCT07335341 shows while recruiting
NCT07335341 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Liberant Thrombectomy System is the first listed.
NCT07335341 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07335341 about?
NCT07335341 is a clinical study titled "Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System". The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for ...
What is the current status of trial NCT07335341?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2026-02-24. Estimated completion is 2026-10.
What interventions are being tested in trial NCT07335341?
The interventions under investigation include: Liberant Thrombectomy System (DEVICE).
Who is sponsoring clinical trial NCT07335341?
This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI